Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Fludarabine (Fludara)

9 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Supportive Care

    VICCPED1619

    02/19/2016

    An Expanded Access Study of the Feasibility of Using the CliniMACS? Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients

    Treatment

    VICCBMT17102

    01/09/2018

    A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

    Treatment

    VICCBMT15116

    01/03/2018

    A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

    Treatment

    VICCHEM16156

    07/17/2017

    A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

    Treatment

    VICCPED15143

    02/15/2017

    A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory Bprecursor Acute Lymphoblastic Leukemia (r/r ALL)

    Treatment

    VICCHEM1597

    02/17/2016

    A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

    Treatment

    VICCHEM1423

    08/08/2014

    A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

    Treatment

    VICCNCPED1414

    04/24/2014

    HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, TBI and Fludarabine; Postgrafting Immunosuppression will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus

    Treatment

    VICCNCBMT12108

    05/08/2013

    A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies


    Print this page for your doctor